Limits...
The Neuroprotective Mechanism of Low-Frequency rTMS on Nigral Dopaminergic Neurons of Parkinson's Disease Model Mice.

Dong Q, Wang Y, Gu P, Shao R, Zhao L, Liu X, Wang Z, Wang M - Parkinsons Dis (2015)

Bottom Line: Results.Conclusions.Low-frequency rTMS had a neuroprotective effect on the nigral dopaminergic neuron which might be due to the improved expressions of brain derived neurotrophic factor and glial cell line-derived neurotrophic factor.

View Article: PubMed Central - PubMed

Affiliation: Fifth Department of Neurology, Cangzhou Central Hospital, No. 16 Xinhua Western Road, Cangzhou, Hebei 061000, China.

ABSTRACT
Background. Parkinson's disease is a neurodegenerative disease in elder people, pathophysiologic basis of which is the severe deficiency of dopamine in the striatum. The purpose of the present study was to evaluate the neuroprotective effect of low-frequency rTMS on Parkinson's disease in model mice. Methods. The effects of low-frequency rTMS on the motor function, cortex excitability, neurochemistry, and neurohistopathology of MPTP-induced Parkinson's disease mice were investigated through behavioral detection, electrophysiologic technique, high performance liquid chromatography-electrochemical detection, immunohistochemical staining, and western blot. Results. Low-frequency rTMS could improve the motor coordination impairment of Parkinson's disease mice: the resting motor threshold significantly decreased in the Parkinson's disease mice; the degeneration of nigral dopaminergic neuron and the expression of tyrosine hydroxylase were significantly improved by low-frequency rTMS; moreover, the expressions of brain derived neurotrophic factor and glial cell line derived neurotrophic factor were also improved by low-frequency rTMS. Conclusions. Low-frequency rTMS had a neuroprotective effect on the nigral dopaminergic neuron which might be due to the improved expressions of brain derived neurotrophic factor and glial cell line-derived neurotrophic factor. The present study provided a theoretical basis for the application of low-frequency rTMS in the clinical treatment and recovery of Parkinson's disease.

No MeSH data available.


Related in: MedlinePlus

The effects of low-frequency rTMS on the content of DA and its metabolites in the striatum of PD model mice. *Significantly different from NS group, P < 0.05; #significantly different from rTMS group, P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4390107&req=5

fig4: The effects of low-frequency rTMS on the content of DA and its metabolites in the striatum of PD model mice. *Significantly different from NS group, P < 0.05; #significantly different from rTMS group, P < 0.05.

Mentions: A dramatic decline of DA level was observed in the striatum of PD mice (Figure 4; Table S4) (P < 0.05). DOPAC and HVA level also decreased compared to NS group (Figure 4; Table S4) (P < 0.05). After low-frequency rTMS treatment, the DA, DOPAC, and HVA levels in rTMS group were significantly increased compared with PD and s-TMS groups (Figure 4; Table S4) (P < 0.05). No significant difference was found between s-rTMS and PD group (Figure 4; Table S4).


The Neuroprotective Mechanism of Low-Frequency rTMS on Nigral Dopaminergic Neurons of Parkinson's Disease Model Mice.

Dong Q, Wang Y, Gu P, Shao R, Zhao L, Liu X, Wang Z, Wang M - Parkinsons Dis (2015)

The effects of low-frequency rTMS on the content of DA and its metabolites in the striatum of PD model mice. *Significantly different from NS group, P < 0.05; #significantly different from rTMS group, P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4390107&req=5

fig4: The effects of low-frequency rTMS on the content of DA and its metabolites in the striatum of PD model mice. *Significantly different from NS group, P < 0.05; #significantly different from rTMS group, P < 0.05.
Mentions: A dramatic decline of DA level was observed in the striatum of PD mice (Figure 4; Table S4) (P < 0.05). DOPAC and HVA level also decreased compared to NS group (Figure 4; Table S4) (P < 0.05). After low-frequency rTMS treatment, the DA, DOPAC, and HVA levels in rTMS group were significantly increased compared with PD and s-TMS groups (Figure 4; Table S4) (P < 0.05). No significant difference was found between s-rTMS and PD group (Figure 4; Table S4).

Bottom Line: Results.Conclusions.Low-frequency rTMS had a neuroprotective effect on the nigral dopaminergic neuron which might be due to the improved expressions of brain derived neurotrophic factor and glial cell line-derived neurotrophic factor.

View Article: PubMed Central - PubMed

Affiliation: Fifth Department of Neurology, Cangzhou Central Hospital, No. 16 Xinhua Western Road, Cangzhou, Hebei 061000, China.

ABSTRACT
Background. Parkinson's disease is a neurodegenerative disease in elder people, pathophysiologic basis of which is the severe deficiency of dopamine in the striatum. The purpose of the present study was to evaluate the neuroprotective effect of low-frequency rTMS on Parkinson's disease in model mice. Methods. The effects of low-frequency rTMS on the motor function, cortex excitability, neurochemistry, and neurohistopathology of MPTP-induced Parkinson's disease mice were investigated through behavioral detection, electrophysiologic technique, high performance liquid chromatography-electrochemical detection, immunohistochemical staining, and western blot. Results. Low-frequency rTMS could improve the motor coordination impairment of Parkinson's disease mice: the resting motor threshold significantly decreased in the Parkinson's disease mice; the degeneration of nigral dopaminergic neuron and the expression of tyrosine hydroxylase were significantly improved by low-frequency rTMS; moreover, the expressions of brain derived neurotrophic factor and glial cell line derived neurotrophic factor were also improved by low-frequency rTMS. Conclusions. Low-frequency rTMS had a neuroprotective effect on the nigral dopaminergic neuron which might be due to the improved expressions of brain derived neurotrophic factor and glial cell line-derived neurotrophic factor. The present study provided a theoretical basis for the application of low-frequency rTMS in the clinical treatment and recovery of Parkinson's disease.

No MeSH data available.


Related in: MedlinePlus